Felipe Bedoya, Ph.D.
Affiliations: | 2009 | University of South Florida, Tampa, FL, United States |
Area:
Molecular Biology, Cell Biology, OncologyGoogle:
"Felipe Bedoya"Parents
Sign in to add mentor| Peter G. Medveczky | grad student | 2009 | University of South Florida | |
| (Identification and characterization of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoma cell lines.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Schmidts A, Marsh LC, Srivastava AA, et al. (2020) Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal For Immunotherapy of Cancer. 8 |
| Xu J, Sai H, Li Y, et al. (2019) Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cellular and Molecular Gastroenterology and Hepatology |
| Ghassemi S, Nunez-Cruz S, O'Connor RS, et al. (2018) Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunology Research |
| Fraietta JA, Lacey SF, Orlando EJ, et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine |
| Ormhøj M, Bedoya F, Frigault MJ, et al. (2017) CARs in the Lead Against Multiple Myeloma. Current Hematologic Malignancy Reports |
| Bedoya F, Frigault MJ, Maus MV. (2017) The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 25: 314-320 |
| Orlando E, Leary R, Lacey SF, et al. (2017) Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. Journal of Clinical Oncology. 35: 137-137 |
| Fraietta JA, Lacey SF, Orlando E, et al. (2017) Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia Blood. 130: 3181-3181 |
| Fraietta JA, Lacey SF, Wilcox NS, et al. (2016) Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia Blood. 128: 57-57 |
| Ghassemi S, Prachi P, Scholler J, et al. (2016) Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control Blood. 128: 4549-4549 |